British Patient Capital has participated in Quell Therapeutics’ USD156 million Series B funding round. The deal is the first life sciences investment from Future Fund: Breakthrough, a GBP375 million programme where British Patient Capital co-invests with private sector investors in innovative R&D-intensive UK companies. Quell Therapeutics (Quell), which is based

NOS 5G Fund, created by NOS and managed by Armilar Venture Partners, and Triple Point Ventures, have co-invested EUR4.4 million in digital health start-up knok.  The investment round also includes participation from previous investors, the Social Innovation Fund and Social and Environmental Impact Fund MSM (Mustard Seed MAZE). The Portuguese